INS and type 1 diabetes mellitus: In our cohort, most patients initiated these therapies to improve glycemic control.This suggests that despite advancements in insulin preparations and diabetestechnology, patients with T1DM still have an interest in using additional adjuvanttherapies to improve glycemic control.